

# Heiner Wedemeyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8572569/publications.pdf>

Version: 2024-02-01

625  
papers

37,567  
citations

3731

89  
h-index

4645

170  
g-index

694  
all docs

694  
docs citations

694  
times ranked

25022  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	3.9	15
2	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	4.4	49
3	Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2022, 226, 441-452.	4.0	18
4	The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2022, 6, 320-333.	4.3	21
5	Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. <i>Journal of Hepatology</i> , 2022, 76, 46-52.	3.7	17
6	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. <i>Hepatology Communications</i> , 2022, 6, 480-495.	4.3	15
7	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. <i>Hepatology Communications</i> , 2022, 6, 621-632.	4.3	2
8	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	7.3	16
9	Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 519-531.	4.7	19
10	Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis. <i>Liver International</i> , 2022, 42, 842-852.	3.9	6
11	Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , 2022, 71, 2300-2312.	12.1	37
12	Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. <i>European Journal of Immunology</i> , 2022, 52, 472-483.	2.9	8
13	Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 696-702.	2.0	4
14	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	3.7	54
15	Hepatitis E virus is highly resistant to alcohol-based disinfectants. <i>Journal of Hepatology</i> , 2022, 76, 1062-1069.	3.7	11
16	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. <i>Virus Evolution</i> , 2022, 8, veac007.	4.9	10
17	Apoptosis sensitivity of hepatocellular carcinoma to sorafenib-based treatment combinations depends on the expression pattern of BH3-only proteins. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
18	Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0

#	ARTICLE	IF	CITATIONS
19	Hepatitis B surface antigen induces nuclear accumulation of YAP, thereby driving BMI1-associated hepatocarcinogenesis. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
20	Reverse Inflammaging: Biological age is accelerated in chronic HCV patients and decelerates after HCV cure. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
21	Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2022, , .	2.0	2
22	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis. <i>Scientific Reports</i> , 2022, 12, 3285.	3.3	0
23	Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems. <i>Cells</i> , 2022, 11, 927.	4.1	6
24	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	2.0	14
25	Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study. <i>Critical Care</i> , 2022, 26, 92.	5.8	8
26	Global multi-stakeholder endorsement of the MAFLD definition. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 388-390.	8.1	135
27	Elevated fractional donorâ€derived cellâ€free DNA during subclinical graft injury after liver transplantation. <i>Liver Transplantation</i> , 2022, 28, 1911-1919.	2.4	12
28	FIB-4 and APRI as Predictive Factors for Short- and Long-Term Survival in Patients with Transjugular Intrahepatic Portosystemic Stent Shunts. <i>Biomedicines</i> , 2022, 10, 1018.	3.2	2
29	Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. <i>Critical Care</i> , 2022, 26, 134.	5.8	21
30	Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-8.	1.5	0
31	Homeâ€based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 529-539.	3.7	5
32	Tâ€cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide. <i>Liver International</i> , 2022, 42, 1770-1771.	3.9	7
33	Bulevirtide with or without pegIFNÎ± for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. <i>Journal of Hepatology</i> , 2022, 77, 1422-1430.	3.7	54
34	Diet-refractory NASH in an elderly woman. <i>Gut</i> , 2021, 70, 1924-1945.	12.1	0
35	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
36	A transient early HBVâ€DNA increase during PEGâ€IFNÎ± therapy of hepatitis D indicates loss of infected cells and is associated with HDVâ€RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Residual low HDV viraemia is associated HDV RNA relapse after PEGâ€FNâ€based antiviral treatment of hepatitis delta: Results from the HIDITâ€H study. <i>Liver International</i> , 2021, 41, 295-299.	3.9	18
38	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	3.7	68
39	T cell receptor repertoires within liver allografts are different to those in the peripheral blood. <i>Journal of Hepatology</i> , 2021, 74, 1167-1175.	3.7	9
40	Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAgâ€Negative CHB. <i>Hepatology Communications</i> , 2021, 5, 97-111.	4.3	16
41	Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany. <i>Journal of Viral Hepatitis</i> , 2021, 28, 196-204.	2.0	37
42	<sup>68</sup> Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1235-1241.	5.0	39
43	Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13553.	1.7	4
44	Establishment of a transgenic, single-nodule model of liver cancer in a fibrotic background. , 2021, 59, .		0
45	Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. <i>Biomedicines</i> , 2021, 9, 58.	3.2	6
46	Role of autophagy in amiodarone-mediated hepatotoxicity. , 2021, 59, .		0
47	Increase of Î±-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. <i>Oncolmmunology</i> , 2021, 10, 1874159.	4.6	9
48	Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic Tâ€Cell Responses in a Mouse Model. <i>Hepatology Communications</i> , 2021, 5, 865-881.	4.3	4
49	Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 486-496.	3.8	5
50	Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. <i>Journal of Autoimmunity</i> , 2021, 117, 102591.	6.5	32
51	Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis. <i>Viruses</i> , 2021, 13, 346.	3.3	7
52	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , 2021, 9, 353.	3.2	18
53	Significant compartmentâ€specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , 2021, 41, 1815-1823.	3.9	4
54	Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Realâ€world data from the German Hepatitis Câ€Registry. <i>Liver International</i> , 2021, 41, 949-955.	3.9	8

#	ARTICLE	IF	CITATIONS
55	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. <i>Blood</i> , 2021, 138, 350-353.	1.4	145
56	Hepatitis E: An update on One Health and clinical medicine. <i>Liver International</i> , 2021, 41, 1462-1473.	3.9	63
57	Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. <i>Journal of Hepatology</i> , 2021, 74, 1243-1244.	3.7	44
58	Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection. <i>Frontiers in Immunology</i> , 2021, 12, 684424.	4.8	13
59	The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2021, 41, 2046-2058.	3.9	3
60	Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008â€”2019. <i>Frontiers in Public Health</i> , 2021, 9, 667253.	2.7	3
61	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addictionâ€”A Real-world Experience. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab325.	0.9	3
62	Only partial improvement in healthâ€”related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a realâ€”world settingâ€”results from the German Hepatitis Câ€”Registry (DHCâ€”R). <i>Journal of Viral Hepatitis</i> , 2021, 28, 1206-1218.	2.0	13
63	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021, 74, 72-82.	7.3	19
64	Distinct Immune Imprints of Postâ€”Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , 2021, 27, 887-899.	2.4	4
65	Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. <i>Health Science Reports</i> , 2021, 4, e290.	1.5	8
66	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00371.	2.5	6
67	Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. <i>Cells</i> , 2021, 10, 1471.	4.1	9
68	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	4.1	13
69	An unusual cause of erythema on both lower legs in a patient with Crohn's disease. <i>Gastroenterology</i> , 2021, , .	1.3	1
70	Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. <i>Medicine (United States)</i> , 2021, 100, e26571.	1.0	13
71	BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. <i>Cell Death and Disease</i> , 2021, 12, 736.	6.3	10
72	Primary sclerosing cholangitis with moderately elevated serumâ€”IgG4 â€” characterization and outcome of a distinct variant phenotype. <i>Liver International</i> , 2021, , .	3.9	1

#	ARTICLE	IF	CITATIONS
73	IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , 2021, 75, 229-231.	3.7	3
74	Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. <i>BMC Gastroenterology</i> , 2021, 21, 296.	2.0	2
75	The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C Registry (DHC). <i>Journal of Viral Hepatitis</i> , 2021, 28, 1474-1483.	2.0	5
76	Endoscopic vacuum assisted closure (E-VAC) of upper gastrointestinal leakages. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1-4.	1.5	5
77	Impact of the COVID-19 pandemic on patients with liver cirrhosis—the experience of a tertiary center in Germany. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, 954-960.	0.5	2
78	Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered”. <i>Journal of Hepatology</i> , 2021, 75, 990-992.	3.7	6
79	New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. <i>Clinics in Liver Disease</i> , 2021, 25, 831-839.	2.1	14
80	Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1185-1193.	1.6	10
81	Low Prevalence of HEV Infection and No Associated Risk of HEV Transmission from Mother to Child among Pregnant Women in Vietnam. <i>Pathogens</i> , 2021, 10, 1340.	2.8	1
82	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 223-229.	1.6	3
83	Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 57.	1.9	13
84	Declining numbers of hepatitis-C-virus-associated liver transplantations in Germany. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, 118, 797-798.	0.9	0
85	A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. <i>Viruses</i> , 2021, 13, 2371.	3.3	12
86	Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1582-1587.	1.6	1
87	Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 388-399.	3.3	56
88	Hepatitis D. , 2020, , 133-137.		0
89	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL&#xAASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	7.3	52
90	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg&#x2013;positive patients treated with peginterferon alfa&#x2013;2a. <i>Liver International</i> , 2020, 40, 324-332.	3.9	13

#	ARTICLE	IF	CITATIONS
91	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	3.7	30
92	Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. <i>Hepatology</i> , 2020, 72, 829-844.	7.3	36
93	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 194-195.	3.7	8
94	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	3.7	208
95	Autoimmune hepatitis induction can occur in the liver. <i>Liver International</i> , 2020, 40, 377-381.	3.9	10
96	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1204-1211.	5.8	74
97	Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. <i>Scientific Reports</i> , 2020, 10, 16533.	3.3	12
98	The burden of hepatitis D – defogging the epidemiological horizon. <i>Journal of Hepatology</i> , 2020, 73, 493-495.	3.7	10
99	Reply to the Letter to the Editor: “Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma”. <i>Liver Cancer</i> , 2020, 9, 363-364.	7.7	0
100	Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. <i>Transplant Infectious Disease</i> , 2020, 23, e13522.	1.7	6
101	Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis. <i>PLoS ONE</i> , 2020, 15, e0236528.	2.5	4
102	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. <i>JHEP Reports</i> , 2020, 2, 100168.	4.9	18
103	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	2.0	47
104	Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health. <i>Pathogens</i> , 2020, 9, 856.	2.8	63
105	Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. <i>Frontiers in Public Health</i> , 2020, 8, 424.	2.7	30
106	EASL recommendations on treatment of hepatitis C: Final update of the series†. <i>Journal of Hepatology</i> , 2020, 73, 1170-1218.	3.7	671
107	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2020, 73, S52-S53.	3.7	54
108	The application of immunoglobulins after liver transplantation influences the occurrence of donor-specific antibody associated complications. <i>Journal of Hepatology</i> , 2020, 73, S252-S253.	3.7	0

#	ARTICLE	IF	CITATIONS
109	HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. <i>BMC Gastroenterology</i> , 2020, 20, 288.	2.0	3
110	Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 341-351.	0.5	5
111	Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis. <i>Advances in Therapy</i> , 2020, 37, 4033-4042.	2.9	18
112	Effects of anti-TNF $\alpha$ treatment on Crohn's disease induced hepatic steatosis. <i>Journal of Hepatology</i> , 2020, 73, S239-S240.	3.7	0
113	Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R). <i>Journal of Hepatology</i> , 2020, 73, S348-S349.	3.7	0
114	Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection. <i>Journal of Hepatology</i> , 2020, 73, S349-S350.	3.7	1
115	Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBsAg negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, S603-S604.	3.7	0
116	Barriers to hepatitis C virus elimination in Germany: why aren't diagnosed patients initiating therapy?. <i>Journal of Hepatology</i> , 2020, 73, S795-S796.	3.7	0
117	Alcoholic liver disease is associated with a poorer survival after radioembolisation for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S897.	3.7	0
118	Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness. <i>Journal of Hepatology</i> , 2020, 73, S350-S351.	3.7	1
119	Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection. <i>Journal of Hepatology</i> , 2020, 73, S833-S834.	3.7	0
120	Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells. <i>Journal of Hepatology</i> , 2020, 73, S503.	3.7	0
121	Reversal of Immunity After Clearance of Chronic HCV Infection – All Reset?. <i>Frontiers in Immunology</i> , 2020, 11, 571166.	4.8	21
122	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	2.0	12
123	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	3.9	16
124	Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury. <i>Liver International</i> , 2020, 40, 1225-1238.	3.9	16
125	Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. <i>Hepatology</i> , 2020, 72, 1177-1190.	7.3	65
126	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020, 73, 696-699.	3.7	39



#	ARTICLE	IF	CITATIONS
127	Autophagy alleviates amiodarone-induced hepatotoxicity. <i>Archives of Toxicology</i> , 2020, 94, 3527-3539.	4.2	13
128	HBV RNA Coamplification May Influence HBV DNA Viral Load Determination. <i>Hepatology Communications</i> , 2020, 4, 983-997.	4.3	4
129	Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. <i>Journal of Clinical Virology</i> , 2020, 129, 104525.	3.1	2
130	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy: Results from the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2020, 27, 690-698.	2.0	24
131	Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 2797.	3.3	6
132	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 1112-1121.	3.7	62
133	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	2.5	2
134	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , 2020, 11, 534731.	4.8	26
135	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	3.9	66
136	Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 169-174.	1.4	6
137	Hepatitis D. , 2020, , 287-298.		1
138	Hippo signaling counter regulates early innate immunity in hepatocytes exposed to Hepatitis B virus. , 2020, 58, .		0
139	Soluble inflammatory molecules do not completely normalize despite early treatment of acute symptomatic hepatitis C. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, .	0.5	0
140	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 841-846.	0.5	4
141	Automated Nucleic Acid Isolation Methods for HDV viral Load Quantification can Lead to viral Load Underestimation. <i>Antiviral Therapy</i> , 2019, 24, 117-123.	1.0	24
142	Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2019, 26, 422-431.	2.0	13
143	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1033-1041.	1.5	13
144	SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1962-1971.	0.6	7

#	ARTICLE	IF	CITATIONS
145	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 889-899.	3.7	52
146	Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13146.	1.7	26
147	PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis. <i>Journal of Hepatology</i> , 2019, 70, e113-e114.	3.7	3
148	LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2019, 70, e129-e130.	3.7	9
149	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019, 70, e110.	3.7	2
150	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2076.	4.8	11
151	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , 2019, 9, 14118.	3.3	14
152	The widespread rarity of HBsAg loss in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 190-192.	8.1	1
153	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , 2019, 71, 673-684.	3.7	25
154	Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 67-74.	1.6	5
155	Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice. <i>Cancer Medicine</i> , 2019, 8, 3793-3802.	2.8	3
156	Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2351-2358.	2.3	35
157	Chronic Hepatitis E is associated with cholangitis. <i>Liver International</i> , 2019, 39, 1876-1883.	3.9	16
158	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019, 71, 301-312.	3.7	62
159	The Effect of Immunosuppression on Coagulation After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1054-1065.	2.4	2
160	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	3.7	11
161	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. <i>Antiviral Therapy</i> , 2019, 24, 133-140.	1.0	9
162	Medication adherence among patients with chronic diseases: a survey-based study in pharmacies. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 505-512.	0.5	40

#	ARTICLE	IF	CITATIONS
163	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , 2019, 156, 1820-1833.	1.3	44
164	Intranuclear inclusions in hepatocellular carcinoma contain autophagy-associated proteins and correlate with prolonged survival. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 164-176.	3.0	10
165	Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R). <i>Substance Abuse: Research and Treatment</i> , 2019, 13, 117822181983584.	0.9	11
166	Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study. <i>Viruses</i> , 2019, 11, 186.	3.3	34
167	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	9.1	128
168	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. <i>PLoS ONE</i> , 2019, 14, e0224751.	2.5	1
169	Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1049-1056.	1.6	7
170	NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. <i>Liver Cancer</i> , 2019, 8, 491-504.	7.7	12
171	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , 2019, 8, 2101.	2.4	5
172	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019, 8, 41-65.	7.7	38
173	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
174	Influenza virus infection as precipitating event of acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, 797-799.	3.7	62
175	Devil hepatitis D: an orphan disease or largely underdiagnosed?. <i>Gut</i> , 2019, 68, 381-382.	12.1	34
176	Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. <i>AIDS Reviews</i> , 2019, 21, 126-134.	1.0	24
177	Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study. <i>Russian Journal of Gastroenterology Hepatology Coloproctology</i> , 2019, 28, 15-26.	1.1	0
178	Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes. , 2019, 57, .		0
179	Viral escape contributes to the failure of hepatitis D virus (HDV)-specific CD8+ T cells and drives population-level evolution of HDV. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
180	The Hippo signalling is induced by Toll-like receptor 4 activation and regulatory balance innate immune responses in liver cells. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0

#	ARTICLE	IF	CITATIONS
181	Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen. <i>Antiviral Therapy</i> , 2018, 23, 211-217.	1.0	53
182	Hepatitis E virus replication and interferon responses in human placental cells. <i>Hepatology Communications</i> , 2018, 2, 173-187.	4.3	40
183	The adverse effects of interferon-free regimens in 149816 chronic hepatitis C treated Egyptian patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1296-1305.	3.7	15
184	Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-17.	2.0	65
185	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , 2018, 217, 1656-1666.	4.0	57
186	Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. <i>Liver International</i> , 2018, 38, 1951-1964.	3.9	44
187	Effect of hepatitis B virus on steatosis in hepatitis C virus coinfected subjects: A multicentre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018, 25, 920-929.	2.0	3
188	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018, 69, 461-511.	3.7	1,489
189	Development and performance of prototype serologic and molecular tests for hepatitis delta infection. <i>Scientific Reports</i> , 2018, 8, 2095.	3.3	13
190	Glecaprevir/Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	27.0	361
191	Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. <i>Addiction</i> , 2018, 113, 868-882.	3.3	72
192	Systemic inflammation and immune cell phenotypes are associated with neuropsychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , 2018, 38, 2317-2328.	3.9	9
193	Letter: the role of direct-acting anti-virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus-induced cirrhosis—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1231-1232.	3.7	0
194	EASL Clinical Practice Guidelines on hepatitis E virus infection. <i>Journal of Hepatology</i> , 2018, 68, 1256-1271.	3.7	425
195	E-xchange. <i>Transplantation</i> , 2018, 102, 1209-1210.	1.0	0
196	Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. <i>Liver International</i> , 2018, 38, 50-58.	3.9	72
197	Hepatitis E virus <sc>ORF</sc> 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , 2018, 38, 266-277.	3.9	18
198	Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (<sc>HDIN</sc>). <i>Liver International</i> , 2018, 38, 842-850.	3.9	72

#	ARTICLE	IF	CITATIONS
199	Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. <i>Liver International</i> , 2018, 38, 834-841.	3.9	9
200	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , 2018, 68, 851-853.	3.7	5
201	Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. <i>Journal of Hepatology</i> , 2018, 68, 663-671.	3.7	48
202	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy248.	0.9	5
203	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 26, 466-475.	2.0	6
204	Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis. <i>Scientific Reports</i> , 2018, 8, 17452.	3.3	22
205	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 856-864.	8.1	43
206	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , 2018, 6, 1188-1198.	3.8	23
207	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018, 13, e0199198.	2.5	6
208	Automated low-flow ascites pump in a real-world setting: complications and outcomes. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1082-1089.	1.6	22
209	Virological heterogeneity of hepatitis delta among Vietnamese populations. <i>Journal of Hepatology</i> , 2018, 68, S491-S492.	3.7	0
210	Bile acid monitoring to support safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2018, 68, S522-S523.	3.7	0
211	Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals. <i>Journal of Hepatology</i> , 2018, 68, S532-S533.	3.7	3
212	Risk factors and seroprevalence of hepatitis E evaluated in frozen serum samples (2002-2003) of pregnant women compared with female blood donors in a Southern region of Brazil. <i>Journal of Medical Virology</i> , 2018, 90, 1856-1862.	5.0	9
213	Human T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 510.	4.8	31
214	Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R). <i>Journal of Hepatology</i> , 2018, 68, S21-S22.	3.7	3
215	Reduction of serum infectivity of hepatitis Delta virus-infected patients treated with Myrcludex B: An in vitro assay to determine infectious units. <i>Journal of Hepatology</i> , 2018, 68, S774.	3.7	1
216	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 584-593.	3.7	95

#	ARTICLE	IF	CITATIONS
217	A virological response to PEG-IFN $\alpha$ treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study. <i>Journal of Hepatology</i> , 2018, 68, S507.	3.7	2
218	Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe. <i>Journal of Hepatology</i> , 2018, 68, S755.	3.7	0
219	Clinical significance of detectable and quantifiable <scp>HCV RNA</scp> at the end of treatment with ledipasvir/sofosbuvir in <scp>GT</scp>1 patients. <i>Liver International</i> , 2018, 38, 1906-1910.	3.9	18
220	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. <i>Journal of Hepatology</i> , 2018, 69, 982-984.	3.7	22
221	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , 2018, 35, 843-857.	2.7	17
222	Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. <i>PLoS ONE</i> , 2018, 13, e0197544.	2.5	12
223	Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study. <i>Journal of Hepatology</i> , 2018, 68, S103.	3.7	24
224	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , 2018, 9, 2275.	12.8	75
225	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigenâ€“Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 1480-1484.	4.0	38
226	Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1384-1394.	2.0	19
227	Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial. <i>Journal of Hepatology</i> , 2018, 68, S90.	3.7	9
228	Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2018, 68, S3.	3.7	98
229	Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. <i>International Journal of Cardiology</i> , 2018, 266, 100-105.	1.7	6
230	Interferonâ€“free therapy of chronic hepatitis C with directâ€“acting antivirals does not change the shortâ€“term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 516-525.	3.7	65
231	Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity. <i>Cell Stress</i> , 2018, 2, 216-218.	3.2	3
232	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
233	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1131-1139.	3.9	15
234	Persistent neuropsychiatric impairment in <scp>HCV</scp> patients despite clearance of the virus?!. <i>Journal of Viral Hepatitis</i> , 2017, 24, 541-550.	2.0	38

#	ARTICLE	IF	CITATIONS
235	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. <i>Antiviral Research</i> , 2017, 141, 116-123.	4.1	9
236	Exacerbation d'™infection par le virus de l'™hÃ©patite E au cours d'™un traitement par anti-TNF±. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 244-247.	0.0	0
237	Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. <i>Liver International</i> , 2017, 37, 1468-1475.	3.9	8
238	Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 936-943.	2.0	48
239	Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 939-945.	1.6	35
240	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	3.7	11
241	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. <i>Journal of Clinical Virology</i> , 2017, 93, 46-52.	3.1	13
242	Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2017, 24, 840-849.	2.0	43
243	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , 2017, 245, 14-18.	2.1	32
244	Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 539-546.	1.6	35
245	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 848-856.	0.5	16
246	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 609-618.	3.2	10
247	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. <i>Journal of Hepatology</i> , 2017, 67, 1334-1339.	3.7	32
248	Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. <i>Hepatology</i> , 2017, 66, 1794-1804.	7.3	25
249	Reply to Letter to the Editor. <i>Current Opinion in Virology</i> , 2017, 23, 131.	5.4	0
250	Hepatitis E virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17086.	30.5	386
251	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 215-222.	9.1	109
252	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017, 215, 139-149.	4.0	32

#	ARTICLE	IF	CITATIONS
253	Exacerbation of hepatitis E virus infection during anti-TNF $\alpha$ treatment. <i>Joint Bone Spine</i> , 2017, 84, 217-219.	1.6	9
254	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017, 65, 414-425.	7.3	88
255	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551.	3.7	624
256	Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017, 37, 196-204.	3.9	42
257	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. <i>Frontiers in Immunology</i> , 2017, 8, 525.	4.8	25
258	Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2017, 8, 621.	4.8	48
259	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw572.	3.0	1
260	Clinical Impact of Liver Biopsies in Liver Transplant Recipients. <i>Annals of Transplantation</i> , 2017, 22, 108-114.	0.9	11
261	Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam. <i>PLoS ONE</i> , 2017, 12, e0175304.	2.5	16
262	Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. <i>PLoS ONE</i> , 2017, 12, e0189255.	2.5	47
263	<i>SOCS3</i> genetic variants and promoter hypermethylation in patients with chronic hepatitis B. <i>Oncotarget</i> , 2017, 8, 17127-17139.	1.8	24
264	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 187-192.	1.6	7
265	Low Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study. <i>Intervirology</i> , 2016, 59, 254-255.	2.8	80
266	The role of zinc in liver cirrhosis. <i>Annals of Hepatology</i> , 2016, 15, 7-16.	1.5	137
267	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	4.4	61
268	Nonreversible MAIT cell dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. <i>European Journal of Immunology</i> , 2016, 46, 2204-2210.	2.9	142
269	Flares during long-term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1882-1887.	2.8	10
270	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	2.8	4



#	ARTICLE	IF	CITATIONS
271	Cross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection. <i>Journal of Viral Hepatitis</i> , 2016, 23, 305-315.	2.0	27
272	Extrahepatic replication and infection of hepatitis E virus in neuronal-derived cells. <i>Journal of Viral Hepatitis</i> , 2016, 23, 512-521.	2.0	104
273	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. <i>Gut</i> , 2016, 65, 1015-1023.	12.1	7
274	Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. <i>Gut</i> , 2016, 65, 1861-1870.	12.1	166
275	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , 2016, 81, 82-89.	3.1	60
276	Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 361-368.	4.0	52
277	Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment. <i>Medical Microbiology and Immunology</i> , 2016, 205, 263-268.	4.8	6
278	How to diagnose and manage hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 146-152.	1.6	31
279	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , 2016, 65, 473-482.	3.7	64
280	Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. <i>Journal of Hepatology</i> , 2016, 65, 490-498.	3.7	321
281	Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2016, 80, 1-7.	3.1	13
282	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). <i>Lancet Infectious Diseases</i> , The, 2016, 16, 606-617.	9.1	118
283	Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016, 214, 1492-1497.	4.0	114
284	Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". <i>Journal of Hepatology</i> , 2016, 65, 1059-1060.	3.7	0
285	Real-World Safety and Effectiveness of Ombitasvir/ Paritaprevir/R with Dasabuvir and/or Ribavirin in the German Hepatitis C Registry. <i>Journal of Hepatology</i> , 2016, 64, S159.	3.7	11
286	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , 2016, 65, 1733-1743.	12.1	145
287	Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2016, 214, 1965-1974.	4.0	127
288	Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 546-547.	3.7	6

#	ARTICLE	IF	CITATIONS
289	HBsAg kinetics in chronic hepatitis D during interferon therapy: onâ€treatment prediction of response. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 620-628.	3.7	43
290	Hepatitis E Virus Mutations: Functional and Clinical Relevance. <i>EBioMedicine</i> , 2016, 11, 31-42.	6.1	52
291	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. <i>Hepatology</i> , 2016, 64, 2274-2276.	7.3	7
292	Antiviral therapy of hepatitis delta virus infection â€” progress and challenges towards cure. <i>Current Opinion in Virology</i> , 2016, 20, 112-118.	5.4	32
293	The hepatitis E virus: a likely cause of extrahepatic diseases!. <i>Liver International</i> , 2016, 36, 473-476.	3.9	3
294	Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-Câ”03:04 and modulate NK cell function. <i>Journal of Hepatology</i> , 2016, 65, 252-258.	3.7	43
295	Creating an effective clinical registry for rare diseases. <i>United European Gastroenterology Journal</i> , 2016, 4, 333-338.	3.8	31
296	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1168-1176.	2.8	44
297	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus reâ€infection after liver transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 326-332.	1.7	42
298	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2132-2139.	3.2	75
299	Hepatitis C virus infection from the perspective of heterologous immunity. <i>Current Opinion in Virology</i> , 2016, 16, 41-48.	5.4	22
300	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	5.8	23
301	Drugâ€Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, 561-567.	5.8	89
302	Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. <i>PLoS ONE</i> , 2016, 11, e0145409.	2.5	6
303	Hepatitis E. , 2016, , 69-73.		0
304	Hepatitis E. , 2016, , 69-73.		0
305	Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection. <i>Blood</i> , 2016, 128, 4898-4898.	1.4	0
306	HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. <i>Antiviral Therapy</i> , 2015, 20, 177-183.	1.0	17

#	ARTICLE	IF	CITATIONS
307	Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan?. EBioMedicine, 2015, 2, 1564-1565.	6.1	5
308	Estimating <scp>HCV</scp> disease burden â€“ volume 3 (editorial). Journal of Viral Hepatitis, 2015, 22, 1-3.	2.0	13
309	Highâ€resolution determination of human immune cell signatures from fineâ€needle liver aspirates. European Journal of Immunology, 2015, 45, 2154-2157.	2.9	23
310	Improvement of liver function parameters in advanced <scp>HCV</scp>â€associated liver cirrhosis by <scp>IFN</scp>â€free antiviral therapies. Alimentary Pharmacology and Therapeutics, 2015, 42, 889-901.	3.7	111
311	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology, 2015, 62, 1013-1023.	7.3	46
312	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfaâ€2a in hepatitis C null responders. Liver International, 2015, 35, 2275-2284.	3.9	0
313	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. Journal of Viral Hepatitis, 2015, 22, 1020-1032.	2.0	10
314	99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin. American Journal of Gastroenterology, 2015, 110, S850-S851.	0.4	4
315	Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin. American Journal of Gastroenterology, 2015, 110, S862.	0.4	4
316	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. Frontiers in Immunology, 2015, 6, 270.	4.8	27
317	Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS ONE, 2015, 10, e0138503.	2.5	3
318	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEx Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. PLoS ONE, 2015, 10, e0128069.	2.5	5
319	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS ONE, 2015, 10, e0145622.	2.5	2
320	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clinical Gastroenterology and Hepatology, 2015, 13, 2342-2349.e2.	4.4	57
321	Altered effector functions of NK cells in chronic hepatitis C are associated with <i>IFNL3</i> polymorphism. Journal of Leukocyte Biology, 2015, 98, 283-294.	3.3	11
322	Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays. Intervirology, 2015, 58, 283-287.	2.8	13
323	Eligibility and safety of the first interferonâ€free therapy against hepatitis C in a realâ€world setting. Liver International, 2015, 35, 1845-1852.	3.9	25
324	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut, 2015, 64, 1289-1295.	12.1	178

#	ARTICLE	IF	CITATIONS
325	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1057-1064.	2.8	4
326	Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. <i>Clinical Microbiology and Infection</i> , 2015, 21, 606.e1-606.e10.	6.0	108
327	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8 <sup>+</sup> T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , 2015, 89, 8304-8317.	3.4	32
328	The New Era of Interferon-Free Treatment of Chronic Hepatitis C. <i>Visceral Medicine</i> , 2015, 31, 290-296.	1.3	19
329	P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. <i>Journal of Hepatology</i> , 2015, 62, S524-S525.	3.7	5
330	P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline?. <i>Journal of Hepatology</i> , 2015, 62, S571-S572.	3.7	0
331	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon- $\gamma$ -induced protein 10 levels in HBV/HCV-coinfected patients. <i>Clinical Microbiology and Infection</i> , 2015, 21, 710.e1-710.e9.	6.0	48
332	Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells. <i>Journal of Immunology</i> , 2015, 194, 2467-2471.	0.8	238
333	Evaluation of the COBAS <sup>®</sup> AmpliPrep/COBAS <sup>®</sup> TaqMan <sup>®</sup> HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. <i>Journal of Clinical Virology</i> , 2015, 67, 67-72.	3.1	18
334	Effects of HDV infection and pegylated interferon $\alpha$ treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , 2015, 64, 469-482.	12.1	51
335	Towards interferon-free treatment for all HCV genotypes. <i>Lancet, The</i> , 2015, 385, 2443-2445.	13.7	22
336	Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1586-1594.	0.6	18
337	Current Management of HBV/HDV Coinfection and Future Perspectives. <i>Current Hepatology Reports</i> , 2015, 14, 284-292.	0.9	4
338	Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopenia and hypoalbuminaemia. <i>Liver International</i> , 2015, 35, 2358-2362.	3.9	15
339	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. <i>Journal of Virological Methods</i> , 2015, 214, 29-32.	2.1	39
340	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	3.7	59
341	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	12.1	30
342	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 31-40.	3.7	50

#	ARTICLE	IF	CITATIONS
343	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. <i>Molecular Immunology</i> , 2015, 63, 320-327.	2.2	25
344	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0134839.	2.5	3
345	In Reply. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2015, 112, 220.	0.9	0
346	Immunopathogenesis of Hepatitis D. , 2014, , 231-241.		0
347	Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis. <i>PLoS ONE</i> , 2014, 9, e85330.	2.5	61
348	In Situ Characterization of Intrahepatic Non-Parenchymal Cells in PSC Reveals Phenotypic Patterns Associated with Disease Severity. <i>PLoS ONE</i> , 2014, 9, e105375.	2.5	20
349	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. <i>PLoS ONE</i> , 2014, 9, e108751.	2.5	15
350	Hepatitis E in Germany. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2014, 111, 577-83.	0.9	75
351	Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. <i>Gut</i> , 2014, 63, 1150-1158.	12.1	41
352	Hepatitis E virus infection in a hematopoietic stem cell donor. <i>Bone Marrow Transplantation</i> , 2014, 49, 159-160.	2.4	31
353	How to Interpret Borderline HCV Antibody Test Results: A Comparative Study Investigating Four Different Anti-HCV Assays. <i>Viral Immunology</i> , 2014, 27, 7-13.	1.3	7
354	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014, 60, 87-97.	7.3	234
355	Treatment of severe, nonfulminant acute hepatitis <sc>B</sc> with lamivudine <i>vs</i> placebo: a prospective randomized double-blind multicentre trial. <i>Journal of Viral Hepatitis</i> , 2014, 21, 744-750.	2.0	24
356	Strategies to manage hepatitis <sc>C</sc> virus (<sc>HCV</sc>) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	2.0	161
357	The impact of hepatitis E in the liver transplant setting. <i>Journal of Hepatology</i> , 2014, 61, 1418-1429.	3.7	115
358	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2014, 34, 1452-1463.	3.9	46
359	Impact of <sc>GB</sc> virus <sc>C</sc> viraemia on clinical outcome in <sc>HIV</sc>-infected patients: a 20-year follow-up study. <i>HIV Medicine</i> , 2014, 15, 245-250.	2.2	16
360	Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 836-845.	1.6	24

#	ARTICLE	IF	CITATIONS
361	High prevalence of hepatitis markers in immigrant populations. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1090-1097.	1.6	35
362	UEG Week Vienna 2014 cutting edge symposium: Today's Science, Tomorrow's Medicine session features the immune system "a driving force in digestive health and disease. <i>United European Gastroenterology Journal</i> , 2014, 2, 149-150.	3.8	1
363	Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1927.	7.4	89
364	Response to letter to the editor: Strategies to reduce <sc>HCV</sc> disease burden and <sc>HCV</sc> transmission need different models, as what works for end-stage liver disease may not work for <sc>HCV</sc> prevalence: a comment on the results presented in <sc>JVH</sc> Special Issue. <i>Journal of Viral Hepatitis</i> , 2014, 21, e169-70.	2.0	4
365	Cost of treating hepatitis C in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1278-1285.	1.6	9
366	Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease. <i>Transplant Infectious Disease</i> , 2014, 16, 958-967.	1.7	0
367	Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 85-92.	3.7	30
368	Development and evaluation of a baseline event anticipation score for hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2014, 21, e154-63.	2.0	54
369	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	2.0	372
370	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014, 34, 1207-1215.	3.9	7
371	ABT-450/Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. <i>New England Journal of Medicine</i> , 2014, 370, 1973-1982.	27.0	834
372	Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis. <i>Journal of Infectious Diseases</i> , 2014, 209, 1362-1373.	4.0	97
373	Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 544-545.	3.7	0
374	A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates With Ribavirin Treatment Failure in Organ Transplant Recipients. <i>Gastroenterology</i> , 2014, 147, 1008-1011.e7.	1.3	171
375	Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program. <i>Journal of Hepatology</i> , 2014, 61, 976-983.	3.7	25
376	HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 678-679.	9.1	73
377	EASL Recognition Awardee for 2014. <i>Journal of Hepatology</i> , 2014, 61, 466-468.	3.7	0
378	Retreatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1604-1614.	27.0	536

#	ARTICLE	IF	CITATIONS
379	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , 2014, 60, 508-520.	7.3	7
380	Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. <i>Transplant Infectious Disease</i> , 2014, 16, 333-339.	1.7	36
381	Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection. <i>Hepatology</i> , 2014, 60, 1112-1113.	7.3	26
382	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and <sc>HCV</sc> genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577.	2.0	19
383	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	3.7	18
384	Efficacy of Immunotherapy With TG4040, Peg-Interferon, and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection. <i>Gastroenterology</i> , 2014, 147, 119-131.e3.	1.3	30
385	P722 PERFORMANCE AND VALUE OF IFN-LAMBDA3 AND IFN-LAMBDA4 GENOTYPING IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 IN A REAL WORLD SETTING. <i>Journal of Hepatology</i> , 2014, 60, S310.	3.7	0
386	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.	3.7	40
387	Safety and performance of liver biopsies in liver transplant recipients. <i>Clinical Transplantation</i> , 2014, 28, 585-589.	1.6	18
388	Hepatitis <sc>C</sc> virus core antigen testing in liver and kidney transplant recipients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 769-779.	2.0	25
389	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e94512.	2.5	17
390	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	2.5	50
391	Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e110857.	2.5	15
392	Virale Hepatitiden: andere virale Infektionen. , 2014, , 1-6.		0
393	Hepatitis E. , 2014, , 1-6.		0
394	Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma. <i>Acta Gastro-Enterologica Belgica</i> , 2014, 77, 386-8.	1.0	1
395	Treatment of hepatitis Delta. <i>Clinical Liver Disease</i> , 2013, 2, 237-239.	2.1	5
396	Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. <i>Journal of Hepatology</i> , 2013, 58, 792-800.	3.7	100

#	ARTICLE	IF	CITATIONS
397	The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1365-1372.	3.7	36
398	Results of single-center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin. <i>Pediatric Transplantation</i> , 2013, 17, 343-347.	1.0	33
399	504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS. <i>Journal of Hepatology</i> , 2013, 58, S207.	3.7	3
400	Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). <i>European Journal of Radiology</i> , 2013, 82, 1207-1212.	2.6	49
401	435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA. <i>Journal of Hepatology</i> , 2013, 58, S178.	3.7	0
402	Hepatitis E virus infection: Multiple faces of an underestimated problem. <i>Journal of Hepatology</i> , 2013, 58, 1045-1046.	3.7	34
403	Treatment Options for Hepatitis Delta Virus Infection. <i>Current Infectious Disease Reports</i> , 2013, 15, 31-38.	3.0	68
404	Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. <i>Liver International</i> , 2013, 33, 722-726.	3.9	150
405	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 497-506.	9.1	84
406	On the fast track towards IFN-free therapy for hepatitis C?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 76-78.	17.8	6
407	Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients. <i>Journal of Virology</i> , 2013, 87, 6172-6181.	3.4	88
408	Immunopathogenesis of Hepatitis E Virus Infection. <i>Seminars in Liver Disease</i> , 2013, 33, 071-078.	3.6	42
409	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. <i>Gut</i> , 2013, 62, 760-765.	12.1	159
410	O232: Hepatitis E: are serologic tests good enough and reliable?. <i>Journal of Viral Hepatitis</i> , 2013, 20, 12-12.	2.0	0
411	Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 1259-1270.	1.2	7
412	PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. <i>Hepatology</i> , 2013, 58, 524-537.	7.3	39
413	Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors. <i>PLoS ONE</i> , 2013, 8, e58340.	2.5	61
414	Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. <i>PLoS ONE</i> , 2013, 8, e55285.	2.5	91



#	ARTICLE	IF	CITATIONS
415	High Prevalence and Significance of Hepatitis D Virus Infection among Treatment-Naïve HBsAg-Positive Patients in Northern Vietnam. PLoS ONE, 2013, 8, e78094.	2.5	30
416	Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon- $\alpha$ 2A Treatment. Antiviral Therapy, 2012, 17, 305-312.	1.0	25
417	Interferon $\alpha$ Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. Journal of Infectious Diseases, 2012, 205, 1351-1362.	4.0	38
418	Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses. Journal of Immunology, 2012, 188, 6055-6062.	0.8	48
419	Hepatitis Delta and HIV Infection. Seminars in Liver Disease, 2012, 32, 120-129.	3.6	23
420	Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy, 2012, 44, 48-52.	1.8	40
421	Gender Differences in Patient Receiving Liver Transplantation for Viral Hepatitis. Zeitschrift Fur Gastroenterologie, 2012, 50, 760-765.	0.5	4
422	Improved Immune Status Corresponds with Long-Term Decline of Quantitative Serum Hepatitis B Surface Antigen in HBV/HIV Co-infected Patients. Viral Immunology, 2012, 25, 442-447.	1.3	15
423	New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: Table 1. Gut, 2012, 61, 1647-1652.	12.1	23
424	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 308, 2584.	7.4	1,327
425	Angiotensin-2 in acute liver failure*. Critical Care Medicine, 2012, 40, 1499-1505.	0.9	22
426	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. Antiviral Therapy, 2012, 17, 1049-1058.	1.0	15
427	Performance of HCV-Core Antigen Testing in Liver Transplanted Patients. Transplantation, 2012, 94, 7.	1.0	0
428	Treatment of Hepatitis E in Solid Organ Transplant Recipients. Transplantation, 2012, 94, 543.	1.0	0
429	Enrichment of Regulatory T Cells in Acutely Rejected Human Liver Allografts. American Journal of Transplantation, 2012, 12, 3425-3436.	4.7	38
430	Natural history of acute and chronic hepatitis C. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 401-412.	2.4	206
431	Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology, 2012, 56, 2398-2403.	7.3	31
432	HBsAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver International, 2012, 32, 1415-1425.	3.9	52

#	ARTICLE	IF	CITATIONS
433	Interferon-Î± for Patients with Chronic Hepatitis Delta: A Systematic Review of Randomized Clinical Trials. <i>Antiviral Therapy</i> , 2012, 17, 1029-1037.	1.0	21
434	Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. <i>Journal of Hepatology</i> , 2012, 56, 115-122.	3.7	74
435	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	3.7	114
436	High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1063-1069.	3.7	35
437	Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: A model-based analysis. <i>Journal of Hepatology</i> , 2012, 57, 260-266.	3.7	22
438	HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. <i>Journal of Clinical Virology</i> , 2012, 53, 110-115.	3.1	30
439	Pathogenesis and Treatment of Hepatitis E Virus Infection. <i>Gastroenterology</i> , 2012, 142, 1388-1397.e1.	1.3	279
440	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. <i>Antiviral Research</i> , 2012, 96, 51-58.	4.1	2
441	Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients. <i>Gastroenterology Insights</i> , 2012, 4, 28.	1.2	7
442	Update on the Management of HBV-HDV Coinfection. <i>Current Hepatitis Reports</i> , 2012, 11, 95-101.	0.3	0
443	Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-8.	2.0	44
444	Chronic Hepatitis E in Heart Transplant Recipients. <i>American Journal of Transplantation</i> , 2012, 12, 3128-3133.	4.7	137
445	Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, 387-395.	2.0	6
446	Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks. <i>Journal of Viral Hepatitis</i> , 2012, 19, 537-546.	2.0	62
447	Chronic hepatitis E in hematopoietic stem cell transplant patients in a low endemic country?. <i>Transplant Infectious Disease</i> , 2012, 14, 103-106.	1.7	38
448	Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. <i>Hepatology</i> , 2012, 55, 695-708.	7.3	158
449	Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. <i>PLoS ONE</i> , 2012, 7, e43143.	2.5	42
450	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 560-568.	1.1	22

#	ARTICLE	IF	CITATIONS
451	Acute HCV. , 2012, , 13-20.		0
452	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology, 2011, 46, 1092-1098.	1.5	94
453	Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Digestive and Liver Disease, 2011, 43, 491-497.	0.9	120
454	1255 CHRONIC HEPATITIS E IN IMMUNOSUPPRESSED PATIENTS BEYOND LIVER- AND KIDNEY TRANSPLANTATION. Journal of Hepatology, 2011, 54, S495.	3.7	4
455	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. Journal of Clinical Virology, 2011, 50, 292-296.	3.1	76
456	Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. Journal of Hepatology, 2011, 54, 1273-1285.	3.7	122
457	Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. Journal of Hepatology, 2011, 55, 38-44.	3.7	51
458	The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5 $\Delta$ 32 mutation. Journal of Hepatology, 2011, 55, 1201-1206.	3.7	20
459	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology, 2011, 55, 1121-1131.	3.7	280
460	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. Journal of Hepatology, 2011, 55, 554-563.	3.7	47
461	358 COMPARING THE LONG-TERM OUTCOME OF HEPATITIS DELTA AND HBV MONOINFECTION: IS HDV-INFECTION REALLY WORSE?. Journal of Hepatology, 2011, 54, S144.	3.7	1
462	382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX. Journal of Hepatology, 2011, 54, S153.	3.7	2
463	772 SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYCLOPHILIN A AND THEIR INFLUENCE ON HCV RNA REPLICATION IN VITRO. Journal of Hepatology, 2011, 54, S310-S311.	3.7	0
464	Hepatitis delta virus. Lancet, The, 2011, 378, 73-85.	13.7	470
465	Is there a need for liver disease monitoring in HIV patients in Africa?. Antiviral Therapy, 2011, 16, 287-289.	1.0	3
466	Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues. Antiviral Therapy, 2011, 16, 915-924.	1.0	76
467	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. Journal of Viral Hepatitis, 2011, 18, 562-570.	2.0	24
468	Adefovir serum levels do not differ between responders and nonresponders. Journal of Viral Hepatitis, 2011, 18, e175-8.	2.0	1

#	ARTICLE	IF	CITATIONS
469	Development of a protocol for the quantitative determination of HBeAg using the Elecsys <sup>®</sup> HBeAg immunoassay. <i>Journal of Viral Hepatitis</i> , 2011, 18, e179-83.	2.0	17
470	Hepatitis D revival. <i>Liver International</i> , 2011, 31, 140-144.	3.9	37
471	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. <i>Liver International</i> , 2011, 31, 1395-1405.	3.9	42
472	Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study. <i>Antiviral Research</i> , 2011, 92, 90-95.	4.1	22
473	Telomerase gene mutations are associated with cirrhosis formation. <i>Hepatology</i> , 2011, 53, 1608-1617.	7.3	143
474	Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 60-69.	7.3	166
475	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. <i>Hepatology</i> , 2011, 54, 443-451.	7.3	150
476	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , 2011, 54, 1947-1955.	7.3	255
477	Hepatitis E: An Emerging Infectious Disease in Germany?. <i>Zeitschrift Fur Gastroenterologie</i> , 2011, 49, 1255-1257.	0.5	26
478	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. <i>Journal of Virology</i> , 2011, 85, 7613-7621.	3.4	40
479	Successful clearance of hepatitis C virus with pegylated interferon $\alpha$ -2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1343-1344.	0.9	11
480	Republished paper: Managing HBV in patients with impaired immunity. <i>Postgraduate Medical Journal</i> , 2011, 87, 223-238.	1.8	3
481	Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2648-2656.	0.7	13
482	Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay. <i>Vaccine Journal</i> , 2011, 18, 1943-1950.	3.1	35
483	Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. <i>New England Journal of Medicine</i> , 2011, 364, 322-331.	27.0	401
484	Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. <i>PLoS Pathogens</i> , 2011, 7, e1002045.	4.7	102
485	Simultaneous Mitral Valve Replacement and Liver Transplantation. <i>Thoracic and Cardiovascular Surgeon</i> , 2011, 59, 506-508.	1.0	5
486	Hepatitis E in HIV-positive patients in a low-endemic country. <i>Journal of Viral Hepatitis</i> , 2010, 17, 598-599.	2.0	37

#	ARTICLE	IF	CITATIONS
487	Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 278-288.	1.6	7
488	Evaluation of Sound Speed for Detection of Liver Fibrosis. <i>Journal of Ultrasound in Medicine</i> , 2010, 29, 1581-1588.	1.7	34
489	The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 356-357.	7.3	13
490	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , 2010, 51, 73-80.	7.3	303
491	Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. <i>Hepatology</i> , 2010, 52, 1611-1620.	7.3	184
492	Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , 2010, 16, 74-82.	2.4	176
493	Hepatitis C new drugs. <i>Journal of the International AIDS Society</i> , 2010, 13, O29.	3.0	1
494	Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , 2010, 30, 430-437.	3.9	96
495	Managing HBV in patients with impaired immunity. <i>Gut</i> , 2010, 59, 1430-1445.	12.1	63
496	Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2022-2029.	3.9	84
497	Membranous Budd-Chiari syndrome in Caucasians. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 226-234.	1.5	19
498	Fulminant Hepatic Failure due to Chemotherapy-Induced Hepatitis B Reactivation: Role of Rituximab. <i>Zeitschrift Fur Gastroenterologie</i> , 2010, 48, 258-263.	0.5	19
499	Of Guinea Pigs and Men – an Unusual Case of Jaundice. <i>Zeitschrift Fur Gastroenterologie</i> , 2010, 48, 33-37.	0.5	4
500	Treatment of HBV/HCV coinfection. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 919-928.	1.8	38
501	Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 31-40.	17.8	342
502	Hepatitis Delta: Immunopathogenesis and Clinical Challenges. <i>Digestive Diseases</i> , 2010, 28, 133-138.	1.9	51
503	EASL transitioning into the new decade. <i>Journal of Hepatology</i> , 2010, 52, 1-2.	3.7	29
504	Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2010, 52, 493-500.	3.7	103

#	ARTICLE	IF	CITATIONS
505	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. <i>Journal of Hepatology</i> , 2010, 52, 514-522.	3.7	355
506	Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV. <i>Journal of Hepatology</i> , 2010, 52, 627-629.	3.7	49
507	The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries. <i>Journal of Hepatology</i> , 2010, 53, 221.	3.7	5
508	Interferon- $\gamma$ -Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 1885-1897.e10.	1.3	177
509	Generation of Human Antigen-Specific Monoclonal IgM Antibodies Using Vaccinated $\alpha$ -Human Immune System Mice. <i>PLoS ONE</i> , 2010, 5, e13137.	2.5	62
510	Chronic hepatitis E in liver transplant recipients: a significant clinical problem?. <i>Minerva Gastroenterologica E Dietologica</i> , 2010, 56, 121-8.	2.2	33
511	Treatment of chronic hepatitis B. <i>Minerva Gastroenterologica E Dietologica</i> , 2010, 56, 451-65.	2.2	14
512	Initial Presentation of Acute Hepatitis C Virus (HCV) Infection among HIV-Negative and HIV-Positive Individuals: Experience from 2 Large German Networks on the Study of Acute HCV Infection. <i>Clinical Infectious Diseases</i> , 2009, 49, 317-319.	5.8	48
513	The German Hep-Net Acute Hepatitis C Cohort: Impact of Viral and Host Factors on the Initial Presentation of Acute Hepatitis C Virus Infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2009, 47, 531-540.	0.5	36
514	Successful Treatment of Fulminant Hepatitis B during Pregnancy. <i>Zeitschrift Fur Gastroenterologie</i> , 2009, 47, 667-670.	0.5	23
515	Adenosine and IFN- $\gamma$ synergistically increase IFN- $\gamma$ production of human NK cells. <i>Journal of Leukocyte Biology</i> , 2009, 85, 452-461.	3.3	15
516	Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. <i>Journal of Immunological Methods</i> , 2009, 342, 33-48.	1.4	26
517	Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. <i>Hepatology</i> , 2009, 49, 1449-1459.	7.3	11
518	Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the Nkp30 receptor. <i>Hepatology</i> , 2009, 50, 799-807.	7.3	532
519	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , 2009, 50, 1638-1645.	7.3	108
520	Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. <i>Journal of Medical Virology</i> , 2009, 81, 2079-2088.	5.0	20
521	Clearance of Chronic HCV Infection During Acute Delta Hepatitis. <i>Infection</i> , 2009, 37, 159-162.	4.7	33
522	Expert opinion on the treatment of patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2009, 16, 75-90.	2.0	215

#	ARTICLE	IF	CITATIONS
523	Virological and clinical characteristics of delta hepatitis in Central Europe. <i>Journal of Viral Hepatitis</i> , 2009, 16, 883-894.	2.0	85
524	HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. <i>Journal of Viral Hepatitis</i> , 2009, 17, 631-9.	2.0	9
525	Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. <i>Liver International</i> , 2009, 29, 1500-1506.	3.9	208
526	Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. <i>Vaccine</i> , 2009, 27, 3099-3108.	3.8	5
527	Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. <i>Journal of Clinical Virology</i> , 2009, 46, 210-215.	3.1	83
528	Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1487-1490.	1.5	55
529	Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 994-1003.	1.5	13
530	Repopulation Efficiencies of Adult Hepatocytes, Fetal Liver Progenitor Cells, and Embryonic Stem Cell-Derived Hepatic Cells in Albumin-Promoter-Enhancer Urokinase-Type Plasminogen Activator Mice. <i>American Journal of Pathology</i> , 2009, 175, 1483-1492.	3.8	106
531	928 EFFECTIVENESS OF TENOFOVIR DF (TDF) MONOTHERAPY IN PATIENTS WITH PRIOR EXPERIENCE TO NUCLEOSIDE/NUCLEOTIDE ANALOGUES BY DIFFERENT PATTERN OF PRE-EXISTING MUTATIONS. <i>Journal of Hepatology</i> , 2009, 50, S337-S338.	3.7	2
532	Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?. <i>Annals of Hepatology</i> , 2009, 8, 166-8.	1.5	5
533	Gilbert's syndrome and antiviral therapy of hepatitis C. <i>Annals of Hepatology</i> , 2009, 8, 246-50.	1.5	7
534	Impaired TRAIL-dependent cytotoxicity of CD11c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2008, 15, 200-211.	2.0	20
535	Kinetics of hepatitis C viral RNA and HCV antigen during dialysis sessions: Evidence for differential viral load reduction on dialysis. <i>Journal of Medical Virology</i> , 2008, 80, 1195-1201.	5.0	27
536	Prevalence of HBV genotypes in Central and Eastern Europe. <i>Journal of Medical Virology</i> , 2008, 80, 1707-1711.	5.0	53
537	GBV-C coinfection is negatively correlated to Fas expression and Fas-mediated apoptosis in HIV-1 infected patients. <i>Journal of Medical Virology</i> , 2008, 80, 1933-1940.	5.0	23
538	Spontaneous clearance of chronic hepatitis C after liver transplantation: Are hepatitis C virus-specific T cell responses the clue?. <i>Liver Transplantation</i> , 2008, 14, 1225-1227.	2.4	15
539	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , 2008, 47, 1856-1862.	7.3	262
540	Natural history: The importance of viral load, liver damage and HCC. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2008, 22, 1063-1079.	2.4	15

#	ARTICLE	IF	CITATIONS
541	Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-Infective Therapy, 2008, 6, 191-199.	4.4	7
542	Medical procedures as a risk factor for HCV infection in developed countries: Do we neglect a significant problem in medical care?. Journal of Hepatology, 2008, 48, 1019-1020.	3.7	25
543	The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon- $\alpha$ 2b and ribavirin in patients with HBV/HCV co-infection. Journal of Hepatology, 2008, 49, 688-694.	3.7	92
544	Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy?. Journal of Hepatology, 2008, 49, 862-863.	3.7	4
545	61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCV E1 THERAPEUTIC VACCINATION. Journal of Hepatology, 2008, 48, S27-S28.	3.7	10
546	638 PARVOVIRUS B19 INFECTION: EVIDENCE FOR INTRAHEPATIC LONG-TERM PERSISTENCE BUT NO ASSOCIATION WITH DISEASE PROGRESSION IN CHRONIC HEPATITIS C. Journal of Hepatology, 2008, 48, S237-S238.	3.7	0
547	Prognostic Implications of Lactate, Bilirubin, and Etiology in German Patients With Acute Liver Failure. Clinical Gastroenterology and Hepatology, 2008, 6, 339-345.	4.4	82
548	Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon $\alpha$ . Journal of Antimicrobial Chemotherapy, 2008, 62, 860-865.	3.0	40
549	Persistence of Occult Hepatitis B after Removal of the Hepatitis B Virus-Infected Liver. Journal of Infectious Diseases, 2008, 197, 355-360.	4.0	30
550	Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4 <sup>+</sup> T-Cell Reactivity. Antimicrobial Agents and Chemotherapy, 2008, 52, 312-320.	3.2	49
551	Pneumococcal Meningitis during Antiviral Treatment with Interferon and Ribavirin in a Splenectomized Patient with Chronic Hepatitis C - Do Not Miss Vaccination before Starting Therapy. Zeitschrift Fur Gastroenterologie, 2008, 46, 880-882.	0.5	8
552	Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrology Dialysis Transplantation, 2008, 24, 179-185.	0.7	76
553	A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels. Antiviral Therapy, 2008, 13, 547-554.	1.0	62
554	Steroid Treatment for Severe Acute Cryptogenic Hepatitis. Zeitschrift Fur Gastroenterologie, 2007, 45, 15-19.	0.5	22
555	Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: The German Guidelines for the Management of HBV Infection. Zeitschrift Fur Gastroenterologie, 2007, 45, 1281-1328.	0.5	63
556	Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Human Molecular Genetics, 2007, 16, 1335-1342.	2.9	45
557	Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis. Annals of Internal Medicine, 2007, 147, 677.	3.9	539
558	Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon $\alpha$ plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. European Journal of Gastroenterology and Hepatology, 2007, 19, 906-909.	1.6	10



#	ARTICLE	IF	CITATIONS
559	Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 91-92.	1.6	9
560	Prevalence of hepatitis C in a German prison for young men in relation to country of birth. <i>Epidemiology and Infection</i> , 2007, 135, 274-280.	2.1	33
561	Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. <i>Journal of Clinical Virology</i> , 2007, 39, 308-311.	3.1	29
562	[98] EFFECTOR/MEMORY SUBSETS AND FUNCTIONALITY OF CD4/CD8+ T-CELLS DURING POTENT ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B (CHB). <i>Journal of Hepatology</i> , 2007, 46, S43-S44.	3.7	0
563	Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. <i>Virology Journal</i> , 2007, 4, 58.	3.4	37
564	Hepatitis D virus infection "Not a vanishing disease in Europe!. <i>Hepatology</i> , 2007, 45, 1331-1332.	7.3	128
565	Hepatitis C virus living off the fat of the land. <i>Hepatology</i> , 2007, 47, 343-345.	7.3	2
566	Longer survival of liver transplant recipients with hepatitis virus coinfections. <i>Clinical Transplantation</i> , 2007, 21, 258-264.	1.6	30
567	Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. <i>European Journal of Clinical Investigation</i> , 2007, 37, 54-64.	3.4	36
568	Immune Responses in Acute and Chronic Hepatitis C. , 2007, , 193-208.		0
569	Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?. <i>Minerva Gastroenterologica E Dietologica</i> , 2007, 53, 337-50.	2.2	0
570	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon- $\alpha$ 2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 303-316.	1.0	22
571	Treating viral hepatitis C: efficacy, side effects, and complications. <i>Gut</i> , 2006, 55, 1350-1359.	12.1	556
572	Treatment of Acute Hepatitis C "How to Explain the Differences?. <i>Gastroenterology</i> , 2006, 131, 682-683.	1.3	5
573	Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. <i>Journal of Hepatology</i> , 2006, 44, 291-301.	3.7	70
574	Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. <i>Journal of Hepatology</i> , 2006, 45, 770-778.	3.7	52
575	Anti-HBc Seroconversion after Transplantation of Anti-HBc Positive Nonliver Organs to Anti-HBc Negative Recipients. <i>Transplantation</i> , 2006, 81, 808-809.	1.0	24
576	Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. <i>Transplant International</i> , 2006, 19, 828-833.	1.6	46

#	ARTICLE	IF	CITATIONS
577	Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. <i>Journal of Viral Hepatitis</i> , 2006, 13, 256-263.	2.0	189
578	Cytotoxic CD4 <sup>+</sup> T cells in viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2006, 13, 505-514.	2.0	130
579	Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2006, 13, 734-741.	2.0	18
580	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006, 43, 250-256.	7.3	229
581	Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. <i>Hepatology</i> , 2006, 43, 1311-1316.	7.3	37
582	Reply:. <i>Hepatology</i> , 2006, 44, 511-512.	7.3	2
583	Dynamics of CD81 expression on lymphocyte subsets during interferon- $\alpha$ -based antiviral treatment of patients with chronic hepatitis C. <i>Journal of Leukocyte Biology</i> , 2006, 80, 298-308.	3.3	10
584	Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006, 12, 3275.	3.3	99
585	Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. <i>Hepatology Research</i> , 2005, 31, 18-23.	3.4	5
586	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. <i>Hepatology</i> , 2005, 41, 832-835.	7.3	174
587	Diagnostic Algorithm for Chronic Hepatitis C Virus Infection: Role of the New HCV-Core Antigen Assay. <i>Zeitschrift Fur Gastroenterologie</i> , 2005, 43, 11-16.	0.5	19
588	Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. <i>Cancer Research</i> , 2005, 65, 2457-2464.	0.9	561
589	Effects of cyclosporine on human dendritic cell subsets. <i>Transplantation Proceedings</i> , 2005, 37, 20-24.	0.6	17
590	Hepatitis B Virus: Where Are We and Where Are We Going?. , 2004, 96, 415-444.		1
591	Treatment of Hepatitis C in HIV-Infected Patients. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2909.	7.4	13
592	Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2004, 1, 24-25.	1.7	2
593	Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. <i>Clinical Microbiology and Infection</i> , 2004, 10, 70-72.	6.0	23
594	Acute hepatitis C infection: Can immunology teach us the right way to treat?. <i>Current Hepatitis Reports</i> , 2004, 3, 148-156.	0.3	3

#	ARTICLE	IF	CITATIONS
595	Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. <i>Hepatology</i> , 2004, 39, 1201-1203.	7.3	37
596	Long-term follow-up after successful interferon therapy of acute hepatitis C. <i>Hepatology</i> , 2004, 40, 98-107.	7.3	80
597	High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. <i>Journal of Medical Virology</i> , 2004, 73, 387-391.	5.0	108
598	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. <i>Gastroenterology</i> , 2004, 127, 1347-1355.	1.3	322
599	Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 41, 999-1007.	3.7	39
600	IN VITRO AND IN VIVO INVESTIGATIONS ON THE EFFECTS OF CYCLOSPORINE ON HUMAN DENDRITIC CELL SUBSETS. <i>Transplantation</i> , 2004, 78, 601-602.	1.0	0
601	Hepatitis C virus mutation affects proteasomal epitope processing. <i>Journal of Clinical Investigation</i> , 2004, 114, 250-259.	8.2	87
602	A rare manifestation of Behçet's syndrome: immunological correlates and successful treatment of an esophageal ulcer. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1385-1391.	2.3	2
603	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. <i>Current Hepatitis Reports</i> , 2003, 2, 24-31.	0.3	1
604	The German network of excellence for viral hepatitis (Hep-Net). <i>Hepatology</i> , 2003, 38, 543-544.	7.3	28
605	Analysis and function of delta-hepatitis virus-specific cellular immune responses. <i>Journal of Hepatology</i> , 2003, 38, 15-16.	3.7	10
606	Immunological, virological and clinical long-term follow-up after interferon therapy of acute hepatitis C infection. <i>Journal of Hepatology</i> , 2003, 38, 181.	3.7	4
607	Acute CMV-Colitis in a Patient with a History of Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 119-122.	1.5	28
608	Acute CMV-colitis in a patient with a history of ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 119-22.	1.5	12
609	Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2002, 169, 3447-3458.	0.8	596
610	Peptide- $\beta$ 2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. <i>Journal of Immunological Methods</i> , 2002, 271, 125-135.	1.4	42
611	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <i>Current Gastroenterology Reports</i> , 2002, 4, 23-30.	2.5	82
612	Polyethylene glycol-interferon: Current status in hepatitis C virus therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S344-50.	2.8	15

#	ARTICLE	IF	CITATIONS
613	Treatment of Acute Hepatitis C with Interferon Alfa-2b. <i>New England Journal of Medicine</i> , 2001, 345, 1452-1457.	27.0	788
614	Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells. <i>Journal of Virology</i> , 2001, 75, 11392-11400.	3.4	215
615	Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. <i>Gut</i> , 2001, 48, 378-383.	12.1	62
616	Genetic Immunization of Wild-Type and Hepatitis C Virus Transgenic Mice Reveals a Hierarchy of Cellular Immune Response and Tolerance Induction against Hepatitis C Virus Structural Proteins. <i>Journal of Virology</i> , 2001, 75, 12121-12127.	3.4	30
617	Hepatitis C and the Leptin System: Bound Leptin Levels Are Elevated in Patients with Hepatitis C and Decrease During Antiviral Therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 426-431.	1.5	20
618	Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 5692-5697.	7.1	401
619	Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during $\alpha$ -interferon treatment. <i>Journal of Hepatology</i> , 1999, 30, 366-375.	3.7	101
620	FAMCICLOVIR TREATMENT OF CHRONIC HEPATITIS B IN HEART TRANSPLANT RECIPIENTS: A PROSPECTIVE TRIAL <sup>1,2</sup> . <i>Transplantation</i> , 1999, 68, 1503-1511.	1.0	22
621	Combination therapy of chronic hepatitis C: an important step but not the final goal!. <i>Journal of Hepatology</i> , 1998, 29, 1010-1014.	3.7	25
622	LONG-TERM OUTCOME OF CHRONIC HEPATITIS B IN HEART TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1998, 66, 1347-1353.	1.0	58
623	Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. <i>Hepato-Gastroenterology</i> , 1998, 45, 1062-8.	0.5	5
624	Deutsches Hepatitis C-Register: Aktuelle Auswertungen und ihre Konsequenzen. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 0, , .	0.9	0
625	Sclerotherapy of Symptomatic Nonparasitic Splenic Cysts: Excellent Long-Term Treatment Response'. <i>Digestive Disease Interventions</i> , 0, , .	0.2	0